Special Issue "New Sight for Clinical Treatment of Pulmonary Hypertension"

Dear Colleagues,

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and the clinical classification of PH categorises these conditions into five groups according to their similar clinical presentation, pathological findings, haemodynamic characteristics, and treatment strategy. In recent years, substantial progress has been made in detecting and managing PH. A multistep, pragmatic approach to diagnosis should be considered in patients with symptoms or signs raising suspicion of PH. In particular, in pulmonary arterial hypertension (PAH), it is important to classify the patient’s risk as low, intermediate, or high risk for clinical worsening or death as this will guide medical treatment. The overall treatment goal in patients with PAH is to achieve a low-risk status, which is associated with good exercise capacity, good quality of life, good RV function, and a low mortality risk. Despite treatment advances in recent years, PH remains a life-shortening condition. The complexity of managing PH requires a multifaceted, holistic, and multidisciplinary approach.

This prepared Special Issue will be devoted to all aspects of clinical treatment of pulmonary hypertension (PH). All researchers are invited to contribute original works and reviews (case reports and short reviews are not accepted).

Dr. Marcel A.M. Beijk
Dr. Mariëlle C. Van de Veerdonk
Prof. Dr. Harm Jan Bogaard
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• pulmonary hypertension
• clinical treatment
• pulmonary arterial hypertension
• chronic thromboembolic pulmonary hypertension
• endothelin receptor antagonists
• phosphodiesterase 5 inhibitors
• guanylate cyclase
• stimulators
• prostacyclin analogues and prostacyclin receptor agonists